Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers

June 03, 2026 By The ASCO Post Staff

Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527). 

Related Content